Atlas Trials

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Clinical trial NCT01966471 · COMPLETED

Trial details

NCT number
NCT01966471
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2014-01-31
Primary completion
2019-11-27
Enrollment
1846

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.